drugset / Trial / NCT04404517
Correlation of Serum Adalimumab Levels at an Administration of 40 mg Weekly vs 80 mg Every Two Weeks
RandomizedCrossoverOpen-labelTreatment
Summary
RCT to evaluate possible pharmacokinetic differences between the two current regimes of intensified adalimumab administration.
Timeline
- Start
- 2019-10-01
- Primary completion
- 2021-09-30
- Completion
- 2021-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Adalimumab | Monoclonal antibody | 40 mg | Subcutaneous |
| Comparator | Adalimumab | Monoclonal antibody | 80 mg | Subcutaneous |